$RGEN (Repligen Corporation)

$RGEN {{ '2016-05-19T13:49:49+0000' | timeago}} • Announcement

$RGEN announced the pricing of an underwritten public offering of $100MM aggregate principal amount of 2.125% Convertible Senior Notes due 2021. The company has granted the underwriters a 30-day option to purchase up to an additional $15MM of notes. The offering is expected to close on or about May 24.

$AGN {{ '2017-12-12T19:07:05+0000' | timeago}} • Announcement

$AGN enters into a buyout deal with $RPRX through a cash tender offer of $0.67 per share, representing a 43% premium of Repros Therapeutics’ Dec. 11th closing price ($0.47). Allergan's subsidiary will acquire Repros, which focuses on developing the drugs for male and female reproductive disorders. The deal is expected to close in 1Q18.

$SGEN {{ '2017-12-11T16:30:10+0000' | timeago}} • Announcement

$SGEN and $BMY highlighted updated interim results from an ongoing phase 1/2 clinical trial evaluating the combination of Adcetris (brentuximab vedotin) and Opdivo (nivolumab) in relapsed or refractory classical Hodgkin lymphoma (HL).

$RGEN {{ '2017-11-07T15:02:00+0000' | timeago}} • Announcement

$RGEN extended a long-term supply agreement with Purolite Life Sciences for the manufacture of Protein A ligands at Repligen’s facilities in Waltham, MA and Lund, Sweden. $RGEN will supply Protein A ligands to Purolite through November 2022, with an option for renewal through 2025.

$TECH {{ '2017-10-31T15:32:14+0000' | timeago}} • Announcement

$TECH has declared a quarterly dividend of $0.32 per share on its common stock. The dividend is payable on November 24, 2017, to shareholders of record on November 10, 2017.

$ISRG {{ '2017-10-19T21:40:26+0000' | timeago}} • Announcement

Worldwide da Vinci procedures grew approx. 15% in 3Q17 as $ISRG shipped 169 da Vinci Surgical Systems during the quarter. With $TRXC already in its sight, Intuitive Surgical will also be eyeing $MDT with much more concern as Medtronic is set to roll out its surgical robot system next year.

$ISRG {{ '2017-10-19T21:22:14+0000' | timeago}} • Announcement

Amidst concern over an emerging competition for its da Vinci Surgical Systems, $ISRG posted its 3Q17 results where revenue increased 18% and profit grew 41%. Recently, the US FDA has shown the green light for $TRXC to market its Senhance Surgical Robotic System, the first system since 2010 to compete head-to-head against $ISRG's da Vinci system.

$SGMO {{ '2017-10-02T16:06:18+0000' | timeago}} • Announcement

$SGMO and $BIVV said the FDA has accepted the Investigational New Drug (IND) application for ST-400, a gene-edited cell therapy candidate for people with transfusion-dependent beta-thalassemia. $SGMO expects to open several clinical sites across the United States and begin enrolling patients in 1H18.

$SGMO {{ '2017-10-02T16:05:15+0000' | timeago}} • Announcement

$SGMO and $BIVV said the FDA has accepted the Investigational New Drug (IND) application for ST-400, a gene-edited cell therapy candidate for people with transfusion-dependent beta-thalassemia. This is as part of exclusive worldwide collaboration to develop and commercialize gene-edited cell therapies for beta-thalassemia and sickle cell disease.

$RGEN {{ '2017-06-23T12:45:15+0000' | timeago}} • Announcement

$RGEN entered into a definitive merger agreement with privately-held Spectrum, Inc. for about $359MM, comprised of $120MM in cash and 6.2MM shares of Repligen stock. The transaction is expected to be completed during 3Q17.

$SGEN {{ '2017-06-15T12:21:22+0000' | timeago}} • Announcement

Pharma firms $SGEN and $BMY presented an interim analysis from the phase 1/2 clinical trial of  lymphoma drugs Adcetris and Opdivo in relapsed or refractory classical Hodgkin lymphoma, at the International Conference on Malignant Lymphoma in Switzerland. The drugs have not been approved, in combination, for the condition or for other indications.

$SGMO {{ '2017-05-11T12:04:01+0000' | timeago}} • Announcement

$SGMO said it is eligible to receive potential milestone payments of up to $475MM, including up to $300MM for the development and commercialization of SB-525 and up to $175MM for additional Hemophilia A gene therapy product candidates that may be developed under the collaboration with $PFE.

$SGMO {{ '2017-05-11T12:03:12+0000' | timeago}} • Announcement

$SGMO said it will be responsible for conducting the SB-525 Phase 1/2 clinical study and certain manufacturing activities. $PFE will be operationally and financially responsible for subsequent research, development, manufacturing and commercialization activities for SB-525 and additional products, if any.

$SGMO {{ '2017-05-11T12:02:25+0000' | timeago}} • Announcement

$SGMO and $PFE announced an exclusive, global collaboration and license agreement for the development and commercialization of gene therapy programs for Hemophilia A, including SB-525, one of $SGMO's four lead product candidates, which $SGMO expects will enter the clinic this quarter. $SGMO will receive a $70MM upfront payment from $PFE.

$AMAG {{ '2017-01-10T13:22:36+0000' | timeago}} • Announcement

$AMAG and $PTN entered into an agreement for exclusive North American rights to develop and commercialize Rekynda. $AMAG will also pay $PTN tiered royalties on net sales ranging from high single-digit to low double-digit percentages. $AMAG expects the transaction to close in 1Q17.

$AMAG {{ '2017-01-10T13:21:11+0000' | timeago}} • Announcement

$AMAG said the expected filing date in the U.S. for a new drug application for Rekynda is in early 2018, with expected approval and launch by early 2019. $AMAG will pay to $PTN $60MM of upfront consideration, up to $80MM contingent upon achieving certain regulatory milestones and up to $300MM contingent upon meeting certain sales milestones.

$AMAG {{ '2017-01-10T13:18:43+0000' | timeago}} • Announcement

$AMAG and $PTN entered into an agreement for exclusive North American rights to develop and commercialize Rekynda (bremelanotide), an investigational product designed for on-demand treatment of hypoactive sexual desire disorder in pre-menopausal women, that has successfully completed two Phase 3 trials.

$RGEN {{ '2016-12-15T12:52:20+0000' | timeago}} • Announcement

$RGEN acquired TangenX Technology Corporation through an all cash transaction of $39MM. $RGEN expects sales of TangenX products to achieve double-digit growth and contribute $7-7.5MM in revenue for 2017. This acquisition is expected to be accretive on both a GAAP EPS and adjusted EPS basis in 2017.

$TECH {{ '2016-10-31T14:59:36+0000' | timeago}} • Webcast

In FY17, $TECH expects overall organic growth to be similar, if not slightly ahead of FY16. The company expects 2Q17 Diagnostics revenue to be relatively flat to the prior year. Adjusted operating margin is expected to improve in 2H17, as Advanced Cell Diagnostics' revenue continues to ramp, producing more volume leverage for the Biotech segment.

$TECH {{ '2016-10-31T14:51:07+0000' | timeago}} • Webcast

$TECH ended 1Q17 with $122MM of cash and short-term available-for-sale investments. The company's long-term debt obligations at the end of 1Q17 stood at $375.9MM, an increase of $245.9MM from the end of 4Q16.

$TECH {{ '2016-10-31T14:47:56+0000' | timeago}} • Webcast

$TECH had $26.1MM of cash from operations in 1Q17, and its investment in CapEx was $2.4MM. The new ERP system that was implemented in July 2016 delayed some customer invoicing until later in the quarter, driving 1Q17-end accounts receivable balance approx. $10MM higher. $TECH expects these outstanding receivables to be fully collected in 2Q17.

Recent Transcripts

ONVO (Organovo Holdings, Inc.)
Thursday, November 9 2017 - 10:00pm
SGMO (Sangamo Biosciences Inc.)
Thursday, November 9 2017 - 10:00pm
TRXC (TransEnterix, Inc.)
Thursday, November 9 2017 - 9:30pm
BTX (BioTime, Inc.)
Thursday, November 9 2017 - 9:30pm
RGEN (Repligen Corporation)
Thursday, November 9 2017 - 1:30pm
QGEN (Qiagen NV)
Tuesday, November 7 2017 - 2:00pm
TXMD (TherapeuticsMD, Inc.)
Monday, November 6 2017 - 1:00pm
SYN (Synthetic Biologics Inc.)
Wednesday, November 1 2017 - 8:30pm
TECH (Bio-Techne Corp.)
Tuesday, October 31 2017 - 1:00pm
SGEN (Seattle Genetics, Inc.)
Thursday, October 26 2017 - 8:30pm
PTN (Palatin Technologies Inc.)
Monday, September 25 2017 - 3:00pm
ONVO (Organovo Holdings, Inc.)
Wednesday, August 9 2017 - 9:00pm
SGMO (Sangamo Biosciences Inc.)
Wednesday, August 9 2017 - 9:00pm
TECH (Bio-Techne Corp.)
Tuesday, August 8 2017 - 1:00pm
TXMD (TherapeuticsMD, Inc.)
Thursday, August 3 2017 - 8:30pm
RGEN (Repligen Corporation)
Thursday, August 3 2017 - 12:31pm
SYN (Synthetic Biologics Inc.)
Thursday, August 3 2017 - 12:30pm
BTX (BioTime, Inc.)
Wednesday, August 2 2017 - 8:30pm
TRXC (TransEnterix, Inc.)
Wednesday, August 2 2017 - 8:30pm
QGEN (Qiagen NV)
Friday, July 28 2017 - 1:00pm

AlphaGraphics you may like